A Phase 3 interventional study of Methotrexate and Ocrelizumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-03.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is one of 9 that started in 2007, is one of 47 in phase 3, and was the 21st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 613 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 85 in phase 3, and was the 34th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who are naive to methotrexate. Patients will be randomized to receive placebo, ocrelizumab 200mg i.v. or ocrelizumab 500mg i.v. on Days 1 and 15. Repeat courses of i.v. treatment will be administered at weeks 24, 52 and 76. All patients will receive concomitant methotrexate (7.5 mg escalating to 20mg p.o. weekly). The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
Drug: Placebo
Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
Drug: Methotrexate · Drug: Ocrelizumab
Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
Drug: Methotrexate · Drug: Ocrelizumab
Oral repeating dose
Intravenous repeating dose
Intravenous repeating dose
Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 52
The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
Time frame: Baseline to Week 52
Percentage of Participants Without Radiographic Progression (RP) at Week 52
RP was defined as a change from Baseline in the modified Total Sharp Score (mTSS) ≤ 0. The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
Time frame: Week 52
Percentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52
Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "none" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum" \[maximum arthritis disease activity\]; patient assessment of pain in the previous 24 hours on a VAS (extreme left end of the line "none" and the extreme right end "unbearable"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.
Time frame: Baseline to Week 52
Percentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52
A participant was in DAS28 remission if their DAS28 score \< 2.6). The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score indicates more disease activity.
Time frame: Week 24 and Week 52
| Milestone | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg |
|---|---|---|---|
| Started | 210 | 200 | 203 |
| Completed | 183 | 180 | 185 |
| Not completed | 27 | 20 | 18 |
| Withdrew: Death | 2 | 2 | 0 |
| Withdrew: Failure to return | 6 | 5 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Violation of selection criteria at entry | 0 | 3 | 1 |
| Withdrew: Administrative/other | 1 | 2 | 1 |
| Withdrew: Insufficient therapeutic response | 10 | 3 | 1 |
| Withdrew: Refused treatment/did not cooperate | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 |
| Withdrew: Adverse event | 3 | 3 | 10 |
The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
| Units on a scale | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg |
|---|---|---|---|
| Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 52 | 1.59 ± 4.815 | 0.66 ± 4.509 | 0.27 ± 2.908 |
RP was defined as a change from Baseline in the modified Total Sharp Score (mTSS) ≤ 0. The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.
| Percentage of participants | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg |
|---|---|---|---|
| Percentage of Participants Without Radiographic Progression (RP) at Week 52 | 51 (44 to 58) | 66.3 (59.5 to 73.1) | 68.8 (62.2 to 75.3) |
Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "none" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum" \[maximum arthritis disease activity\]; patient assessment of pain in the previous 24 hours on a VAS (extreme left end of the line "none" and the extreme right end "unbearable"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.
| Percentage of participants | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg |
|---|---|---|---|
| ACR20 | 57.5 (50.8 to 64.2) | 73 (66.7 to 79.2) | 71 (64.7 to 77.3) |
| ACR50 | 39.6 (33 to 46.3) | 60.7 (53.9 to 67.6) | 54.5 (47.6 to 61.4) |
| ACR70 | 20.3 (14.8 to 25.8) | 38.3 (31.5 to 45.1) | 38 (31.3 to 44.7) |
A participant was in DAS28 remission if their DAS28 score \< 2.6). The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score indicates more disease activity.
| Percentage of participants | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg |
|---|---|---|---|
| Week 24 | 9.7 (5.6 to 13.7) | 19.9 (14.3 to 25.5) | 18 (12.7 to 23.3) |
| Week 52 | 7.2 (3.7 to 10.8) | 27 (20.8 to 33.3) | 28 (21.8 to 34.2) |
Collected over Baseline up to 30 months.. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Treatment Period | 0/207 (0%) | 22/207 (10.6%) | 128/207 (61.8%) |
| Placebo/Ocrelizumab 500 mg - Treatment Period | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Ocrelizumab 200 mg - Treatment Period | 0/196 (0%) | 21/196 (10.7%) | 135/196 (68.9%) |
| Ocrelizumab 200 mg/Ocrelizumab 500 mg - Treatment Period | 0/12 (0%) | 1/12 (8.3%) | 6/12 (50%) |
| Ocrelizumab 500 mg - Treatment Period | 0/202 (0%) | 31/202 (15.3%) | 144/202 (71.3%) |
| Ocrelizumab 500 mg/Ocrelizumab 500 mg - Treatment Period | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Placebo - Safety Follow-up Period | 2/187 (1.1%) | 11/187 (5.9%) | 35/187 (18.7%) |
| Placebo/Ocrelizumab 500 mg - Safety Follow-up Period | 0/9 (0%) | 2/9 (22.2%) | 3/9 (33.3%) |
| Ocrelizumab 200 mg - Safety Follow-up Period | 2/177 (1.1%) | 2/177 (1.1%) | 32/177 (18.1%) |
| Ocrelizumab 200 mg/Ocrelizumab 500 Mg-safety Follow-up Period | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Ocrelizumab 500 mg - Safety Follow-up Period | 1/185 (0.5%) | 4/185 (2.2%) | 49/185 (26.5%) |
| Ocrelizumab 500 mg/Ocrelizumab 500 mg -Safety Follow-up Period | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Placebo - Treatment Period | Placebo/Ocrelizumab 500 mg - Treatment Period | Ocrelizumab 200 mg - Treatment Period | Ocrelizumab 200 mg/Ocrelizumab 500 mg - Treatment Period | Ocrelizumab 500 mg - Treatment Period | Ocrelizumab 500 mg/Ocrelizumab 500 mg - Treatment Period | Placebo - Safety Follow-up Period | Placebo/Ocrelizumab 500 mg - Safety Follow-up Period | Ocrelizumab 200 mg - Safety Follow-up Period | Ocrelizumab 200 mg/Ocrelizumab 500 Mg-safety Follow-up Period | Ocrelizumab 500 mg - Safety Follow-up Period | Ocrelizumab 500 mg/Ocrelizumab 500 mg -Safety Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatic cirrhosisHepatobiliary disorders | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 1/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 1/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| PneumoniaInfections and infestations | 3/207 | 0/10 | 0/196 | 0/12 | 2/202 | 0/6 | 1/187 | 1/9 | 2/177 | 0/11 | 1/185 | 0/6 |
| Abdominal wall infectionInfections and infestations | 0/207 | 0/10 | 0/196 | 1/12 | 0/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/207 | 0/10 | 0/196 | 0/12 | 3/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/207 | 0/10 | 2/196 | 0/12 | 1/202 | 0/6 | 1/187 | 0/9 | 2/177 | 0/11 | 0/185 | 0/6 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/207 | 0/10 | 2/196 | 0/12 | 1/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 1/185 | 0/6 |
| CholelithiasisHepatobiliary disorders | 0/207 | 0/10 | 0/196 | 0/12 | 2/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/207 | 0/10 | 1/196 | 0/12 | 2/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 1/185 | 0/6 |
| Inguinal herniaGastrointestinal disorders | 2/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Event | Placebo - Treatment Period | Placebo/Ocrelizumab 500 mg - Treatment Period | Ocrelizumab 200 mg - Treatment Period | Ocrelizumab 200 mg/Ocrelizumab 500 mg - Treatment Period | Ocrelizumab 500 mg - Treatment Period | Ocrelizumab 500 mg/Ocrelizumab 500 mg - Treatment Period | Placebo - Safety Follow-up Period | Placebo/Ocrelizumab 500 mg - Safety Follow-up Period | Ocrelizumab 200 mg - Safety Follow-up Period | Ocrelizumab 200 mg/Ocrelizumab 500 Mg-safety Follow-up Period | Ocrelizumab 500 mg - Safety Follow-up Period | Ocrelizumab 500 mg/Ocrelizumab 500 mg -Safety Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 21/207 | 4/10 | 56/196 | 0/12 | 64/202 | 1/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 36/207 | 0/10 | 31/196 | 0/12 | 23/202 | 1/6 | 7/187 | 1/9 | 3/177 | 2/11 | 7/185 | 0/6 |
| Bunion operationSurgical and medical procedures | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 1/6 |
| OedemaGeneral disorders | 2/207 | 0/10 | 0/196 | 0/12 | 0/202 | 1/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Sinusitis noninfectiveRespiratory, thoracic and mediastinal disorders | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 1/6 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 2/187 | 0/9 | 0/177 | 0/11 | 0/185 | 1/6 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 1/185 | 1/6 |
| DyslipidaemiaMetabolism and nutrition disorders | 0/207 | 0/10 | 0/196 | 0/12 | 0/202 | 0/6 | 0/187 | 0/9 | 1/177 | 0/11 | 1/185 | 1/6 |
| CystitisInfections and infestations | 3/207 | 0/10 | 4/196 | 0/12 | 4/202 | 1/6 | 1/187 | 0/9 | 1/177 | 0/11 | 0/185 | 0/6 |
| Drug-induced liver injuryHepatobiliary disorders | 18/207 | 0/10 | 28/196 | 0/12 | 27/202 | 0/6 | 0/187 | 0/9 | 0/177 | 0/11 | 0/185 | 0/6 |
| Age, Continuous(Years) | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg | Total |
|---|---|---|---|---|
| Mean | 49.2 ± 12.43 | 50.8 ± 13.17 | 48.6 ± 12.29 | 49.5 ± 12.66 |
| Sex/Gender, Customized(Participants) | Placebo | Ocrelizumab 200 mg | Ocrelizumab 500 mg | Total |
|---|---|---|---|---|
| Female | 153 | 154 | 161 | 468 |
| Male | 54 | 42 | 41 | 137 |
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jun 2007 to primary completion in Jan 2010, 31 months.
Results were first posted in Nov 2020, 10 years 9 months after primary completion. A results delay was requested in Jun 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Ocrelizumab